Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Analyses of immune infiltrate in DIPG murine models after treatment with new oncolytic virus Delta-24-ACT

ABSTRACT: Analyses of immune infiltrate in DIPG murine models after treatment with new oncolytic virus Delta-24-ACT

PROVIDER: PRJNA810049 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Analyses of immune infiltrate in DIPG murine models after treatment with new oncolytic virus Delta-24-ACT

Project description:To better understand the mechanism underlying the therapeutic effect of Delta-24-ACT, we evaluated the triggered immune response. Thus, we intratumorally injected Delta-24-ACT, Delta-24-RGD or PBS (mock group) 3 days after NP53 cell implantation (0D). Then, tumor immune infiltrate was analyzed by NanoString (15 days)

2022-05-11 | GSE197374 | GEO

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.

Project description: Not available

| S-EPMC6538754 | biostudies-literature

The immunopeptidome and proteome of DIPG

Project description:DIPG is a devastating paediatric and young adult brainstem tumour with no cure and a median overall survival of 9 months. Cellular immunotherapy approaches require specific targeting of unique and tumour specific cell surface antigens, however, there is a paucity of known targets for DIPG. Here we used a proteomics platform approach to interrogate an array of patient derived DIPG cell lines to facilitate a multi-omics based approach to identify cell surface protein candidates enriched or unique to DIPG.

2023-09-25 | PXD038271 | Pride

Effect of CBL0137 on DIPG cells

Project description:Diffuse intrinsic pontine glioma (DIPG) is an aggressive and incurable childhood brain tumor for which new treatments are needed. A high throughput drug screen of 3600 pharmaceutical compounds found that anti-malarials, including quinacrine had potent activity against DIPG neurospheres. CBL0137 is a novel anti-cancer compound developed from quinacrine, which targets Facilitates Chromatin Transcription (FACT), a chromatin remodelling complex involved in transcription, replication, and DNA repair. We have found that CBL0137 displays profound cytotoxic activity against a panel of patient derived DIPG cultures, inhibiting cell proliferation and clonogenic potential, restoring tumor suppressor TP53 and Rb activity and inducing cell death through induction of apoptosis. Moreover, in an orthotopic model of DIPG, treatment with CBL0137 significantly extended animal survival. Histone mutations leading to the loss of histone trimethylation result in epigenetic dysregulation driving DIPG tumorigenesis. Treatment with CBL0137 targets this epigenetic defect, restoring both histone H3.3 acetylation and trimethylation and leading to tumor cell death. Combined epigenetic treatment with the histone deacetylase (HDAC) inhibitor panobinostat led to inhibition of the Rb/E2F1 pathway, and increased the enzymatic activity of enhancer of zeste homolog 2 (EZH2), leading to the restoration of H3K27 trimethylation. This combination therapy had synergistic activity against DIPG neurospheres with induction of apoptosis. Consistent with the in vitro results, the combination of CBL0137 and panobinostat significantly prolonged the survival of mice bearing DIPG orthografts suggesting a potential treatment strategy for DIPG.

2021-03-07 | GSE153883 | GEO

Combination of CBL0137 and Panobinostat in DIPG

2021-02-12 | GSE153441 | GEO

Genome-wide chromatin accessibility profile of human DIPG cell lines

Project description:To study the chromatin accessibility across the genome of DIPG-VII, DIPG-IV, and DIPG-XIII cell lines, we performed ATACseq (Assay for Transposase-Accessible Chromatin with high-throughput sequencing).

2023-12-31 | GSE239938 | GEO

ChIP-seq of H3K27ac and H3K27me3 in HSJD-DIPG-007 cell line

Project description:Identification of super enhancer regions in the HSJD-DIPG-007 cell line and the associated genes with these regions. This study aims to evaluate the efficacy of combined use of BET and CBP inhibition in DIPG.

2020-08-01 | E-MTAB-8242 | biostudies-arrayexpress

IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS

Project description: Not available

| S-EPMC8168238 | biostudies-literature

Immunoprofiling of prostate cancer infiltrate

Project description:Immunoprofiling of prostate cancer infiltrate

| PRJNA644438 | ENA

Genome-wide gene expression profile of human DIPG cell lines (ONC201 treatment)

Project description:To study the effect of ONC201 treatment on DIPG-VII, DIPG-IV, and DIPG-XIII cell lines, we treated cell lines and performed RNA-Seq analysis.

2023-12-31 | GSE239939 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data